Recommendation ID
Research is needed to generate robust and relevant data on the effects of treating people with Alzheimer’s disease on both short-term and long-term outcomes, disease progression through relevant health states, and quality of life.
Any explanatory notes
(if applicable)

Source guidance details

Comes from guidance
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease
Date issued
March 2011

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No